MedPath

Adrenas Therapeutics, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

A Study to Determine Eligibility for CAH-301 (A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) [NCT04783181])

Recruiting
Conditions
Congenital Adrenal Hyperplasia
Interventions
Other: Pre-Screening
First Posted Date
2021-11-01
Last Posted Date
2024-08-23
Lead Sponsor
Adrenas Therapeutics Inc
Target Recruit Count
300
Registration Number
NCT05101902
Locations
🇺🇸

Science37, Los Angeles, California, United States

A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)

Phase 1
Recruiting
Conditions
Congenital Adrenal Hyperplasia
Interventions
Biological: AAV BBP-631
First Posted Date
2021-03-05
Last Posted Date
2024-08-06
Lead Sponsor
Adrenas Therapeutics Inc
Target Recruit Count
25
Registration Number
NCT04783181
Locations
🇺🇸

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath